Suchergebnisse - "Antiviral Agents"

PubPharm (9.649)

61

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

enthalten in: The Journal of antimicrobial chemotherapy | 2024

von Henderson, H. | Wohl, D. | Fischer, W. | +8

62

Structural Landscape of nsp Coding Genomic Regions of SARS-CoV-2-ssRNA Genome : A Structural Genomics Approach Toward Identification of Druggable Genome, Ligand-Binding Pockets, and Structure-Based Druggability

enthalten in: Molecular biotechnology | 2024

von Chakraborty, C. | Bhattacharya, M. | Sharma, A. | +3

63

Antiviral discovery in toxic cyanobacteria : Low hanging fruit in the age of pandemics

enthalten in: Journal of phycology | 2024

von Zheng, S. | Lee, V. | Meza-Padilla, I. | +1

64

iDVEIP : A computer-aided approach for the prediction of viral entry inhibitory peptides

enthalten in: Proteomics | 2024

von Kao, H. | Weng, T. | Chen, C. | +3

65

Effectiveness of oseltamivir in reducing COVID-19-related in-hospital deaths : A pharmacoepidemiological study

enthalten in: International journal of antimicrobial agents | 2024

von Leung, C. | Su, L. | Taylor, L. | +2

66

The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance

enthalten in: Antiviral research | 2024

von Schreiber, A. | Rodner, F. | Oberberg, N. | +5

67

An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting Mpro

enthalten in: Bioorganic & medicinal chemistry letters | 2024

von Zhang, J. | Zhao, L. | Bai, Y. | +9

68

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

enthalten in: Bioorganic & medicinal chemistry | 2024

von Carney, D. | Leffler, A. | Bell, J. | +17

69

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

enthalten in: Antiviral research | 2024

von Khatua, K. | Alugubelli, Y. | Yang, K. | +17

70

New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses

enthalten in: Antiviral research | 2024

von Siniavin, A. | Gushchin, V. | Shastina, N. | +14